Thorsten MD - Artiva Biotherapeutics, Chief Officer
ARTV Stock | 10.40 0.22 2.07% |
Executive
Thorsten MD is Chief Officer of Artiva Biotherapeutics, Common
Age | 48 |
Address | 5505 Morehouse Drive, San Diego, CA, United States, 92121 |
Phone | 858 267 4467 |
Web | https://www.artivabio.com |
Similar Executives
Found 11 records | EXECUTIVE Age | ||
Richard Shames | Protagonist Therapeutics | 64 | |
Carena Spivey | Protagonist Therapeutics | N/A | |
David Liu | Protagonist Therapeutics | 74 | |
Scott MD | Protagonist Therapeutics | N/A | |
Matthew JD | Protagonist Therapeutics | 53 | |
Abha Bommireddi | Protagonist Therapeutics | N/A | |
Matthew Gosling | Protagonist Therapeutics | 53 | |
FACP MD | Protagonist Therapeutics | 65 | |
Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
Asif Ali | Protagonist Therapeutics | 50 | |
Carter King | Protagonist Therapeutics | 53 |
Management Performance
Return On Equity | -0.44 |
Artiva Biotherapeutics, Leadership Team
Elected by the shareholders, the Artiva Biotherapeutics,'s board of directors comprises two types of representatives: Artiva Biotherapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artiva. The board's role is to monitor Artiva Biotherapeutics,'s management team and ensure that shareholders' interests are well served. Artiva Biotherapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artiva Biotherapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
David Moriarty, Senior Operations | ||
Neha Krishnamohan, CFO Development | ||
Fred MD, CEO President | ||
Christopher Horan, Chief Officer | ||
Thorsten MD, Chief Officer | ||
Eugene Helsel, Senior Affairs | ||
Peter Flynn, CoFounder Advisor | ||
JD Esq, COO, VP | ||
Javier MD, Senior Affairs | ||
C PharmD, Senior Operations | ||
Heather Raymon, Senior Development |
Artiva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Artiva Biotherapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.44 | ||||
Operating Margin | (23.45) % | ||||
Current Valuation | 120.95 M | ||||
Shares Outstanding | 24.29 M | ||||
Shares Owned By Insiders | 20.64 % | ||||
Shares Owned By Institutions | 89.04 % | ||||
Number Of Shares Shorted | 1.03 M | ||||
Price To Book | 1.26 X | ||||
Price To Sales | 97.12 X | ||||
Revenue | 33.49 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.